CORAL SPRINGS, FL--(Marketwire - June 03, 2011) -
Nutra Pharma Corp. (OTCBB: NPHC
), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected Alampharm
to serve as the exclusive distributor in Lebanon for its Nyloxin™-branded pain relievers.
"We are excited to be working with Alampharm to introduce our Nyloxin products into Lebanon," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As the leading pharmaceutical distributor in Lebanon, Alampharm is the perfect partner to introduce and distribute our products into the Middle East," he added.
Alampharm is a leading pharmaceutical company operating in Lebanon and highly recognized in the Middle East. Alampharm maintains the highest quality customer service by ensuring the safety of the product; they are focused and dedicated towards their customers, who in turn benefit from emerging new healthcare products such as Nyloxin™. Alampharm is continuously introducing Brand Name and Generic Pharmaceuticals that are FDA-approved Vaccines, Injectables, Over-the-counter Drugs, Nutritional Supplements, Health and Beauty Products, and Home Healthcare products into the Lebanese market. Alampharm, located in Beirut, also has medical representatives all over the country in addition to Syria and has been widely serving the pharmaceutical needs of medical institutes, hospitals, clinics, specialized medical facilities, pharmacies, as well as distributing domestically and regionally with great success since 2004.
"We are so enthusiastic about continuing the registration of Nyloxin and introducing it to the market," commented Dr. Khaled Alam, the Chief Executive Officer of Alampharm. "Nyloxin will be promoted through professional medical representatives to Orthopedics, Neurologists, and Oncologists and we will position Nyloxin as the first choice treatment of chronic pain management," he continued. "In other words, the concept of analgesics in Lebanon and Syria will be changed and Nyloxin will constitute a revolution in the concept of pain treatment. The Arab Community is now ready to bring a positive change in their life, and put an end to their highly rated chronic aches. This will be procured by Nyloxin," he concluded.
According to the World Health Organization (WHO), there are 8700 doctors, 3562 pharmacists, and around 4000 nurses in Lebanon. The characteristics of the medical practice in Lebanon include freedom to prescribe medicines, patient's freedom to choose the doctor and direct agreement concerning fees. The physician therefore have the latitude to market any specific brand to their patient population.
Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
Previously, Nutra Pharma announced agreements with distributors in Mexico, Colombia and Venezuela. The drug registration process for both Cobroxin® and Nyloxin™ are currently being pursued in more than 20 countries.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Lebanon distribution of Nyloxin™ through Alampharm should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.